Genetic analysis of the CYP2D6 gene in patients with Parkinson's disease

Metabolism: Clinical and Experimental

Volumn 47, Issue 1, 1998, Pages 94-96

  Tsuneoka, Yutaka ^a   Matsuo, Yoshinori ^b   Ichikawa, Yoshiyuki ^b   Watanabe, Yasuhiro ^b  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOCHROME P450; DNA; NEUROTOXIN;

ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0031951243     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90199-8     Document Type: Article

References (16)

1. Fonne-Pfister R, Bargetzi MJ, Meyer UA: MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148: 1144-1150, 1987
2. Ohta S, Tachikawa O, Makino Y, et al: Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ), a possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci 46:599-605, 1990
3. Jimenez-Jimenez F, Taberunero C, Mena M, et al: Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. J Neurochem 57:81-87, 1991
4. Semchuk KM, Love EJ, Lee RG: Parkinson's disease and exposure to agricultural work and pesticide chemicals. Neurology 42:1328-1335, 1992
5. Barbeau A, Cloutier T, Roy M, et al: Ecogenetics of Parkinson's disease: 4-Hydroxylation of debrisoquine. Lancet 2:1213-1216, 1985
6. Nakamura K, Goto F, Ray WA, et al: Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38:402-408, 1985
7. Alvan G, Bechtel P, Iselius L, et al: Hydroxylation polymorphism of debrisoquine and mephenytoin in European population. Eur J Clin Pharmacol 39:533-537, 1990
8. Armstrong M, Daly AK, Cholerton S, et al: Mutant debrisoquine hydroxylation gene in Parkinson's disease. Lancet 339:1017-1018, 1992
9. Smith CAD, Gough AC, Leigh PN, et al: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377, 1992
10. Tsuneoka Y, Matsuo Y, Iwahashi K, et al: A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J Biochem 114:263-266, 1993
11. Wang S, Huang J, Lai M, et al: Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RELP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:408-410, 1993
12. Yokota H, Tamura S, Furuya H, et al: Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 3:256-263, 1993
13. Johansson I, Oscarson M, Yue QY, et al: Genetic analysis of the Chinese cytochrome P4502D locus: Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459, 1994
14. Ward CD, Gibb WR: Research diagnostic criteria for Parkinson's disease. Adv Neurol 53:245-249, 1990
15. Kan YW, Dozy AM: Polymorphism of DNA sequence adjacent to human β-globin structural gene: Relationship to sickle mutation. Proc Natl Acad Sci USA 75:5631-5635, 1978
16. Johansson I, Lundqvist E, Bertilsson L, et al: Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829, 1993